Massimo Vaghi

Dr. Massimo Vaghi


Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 September 2020 in JVS-Vascular Science
Verified
Journal Article
Open access
Maria PalmieriMaria Palmieri
Maria Palmieri
ACAurora Currò
Aurora Currò
ATAndrea Tommasi
Andrea Tommasi
LSLaura Di Sarno
Laura Di Sarno
GDGabriella Doddato
Gabriella Doddato
MVMassimo Vaghi
Massimo Vaghi
Somatic mosaicism of KRAS gene is currently recognized as the only established molecular basis of arteriovenous malformations (AVM). However, given the limitations of the current technologies, KRAS somatic mutations are detected only in a limited proportion of AVMs and tissue biopsy remains an invasive high risky, sometimes life-threatening, diagnostic procedure. Next-generation sequencing liquid biopsy using cell-free DNA (cfDNA) has emerged as an innovative noninvasive approach for early detection and monitoring of cancer. This approach overcomes the space-time profile constraint of tissue biopsies opens a new scenario for vascular malformations owing to somatic mosaicism. Here, we propose a new approach as a fast noninvasive reliable tool in order to investigate the cfDNA coming from the AVMs. A group of five patients suffering from AVM were selected. Blood samples from peripheral vein and efferent vein from vascular malformation were collected and cfDNA was extracted. The cfDNA libraries were performed using Oncomine Pan-Cancer Cell-Free Assay. We used Ion Proton for sequencing and Ion Reporter Software for analysis (Life Technologies, Carlsbad, Calif). In all cases, either G12D or G12V mutations in KRAS were identified. The mutational load was higher in the efferent vein than in peripheral blood, confirming the causative role of the identified mutation at a somatic level. We demonstrate that cfDNA next-generation sequencing liquid biopsy is able to identify the KRAS mutation detected in affected tissues. Moreover, we have shown that blood sample withdrawal at the lesion site increases variant allele frequency with an order of magnitude above the limit of detection (usually 0.05%), decreasing the risk of a false negative. Finally, the noninvasiveness of the method avoids any risk of bleeding, being easily performed also in children. We propose this technique as the method of choice to better investigate AVMs and consequently to identify the therapy tailored to the genetic defect. This article highlights the importance of using liquid biopsy as a new method to investigate the molecular profile of AVMs. In view of the frequent inaccessibility of vascular tissues owing to the invasiveness of solid biopsy and the relative high incidence of biopsies with low diagnostic power, here we evaluated the efficacy of detecting cfDNA fragments released into the bloodstream from the affected tissue cells. Through a simple blood draw from the efferent vein at the vascular malformation site, the liquid biopsy allowed us to identify KRAS pathogenic mutations piloting a personalized therapeutic approach and opening a new scenario for new therapeutic strategies.

Verified
Journal Article
Open access
PDF file
VIOLA BIANCA SERIOVIOLA BIANCA SERIO
VIOLA BIANCA SERIO
Maria PalmieriMaria Palmieri
Maria Palmieri
LLLorenzo Loberti
Lorenzo Loberti
SGStefania Granata
Stefania Granata
CFChiara Fallerini
Chiara Fallerini
APAnna Maria Pinto
Anna Maria Pinto
Several different nosological classifications have been used over time for vascular malformations (VMs) since clinical and pathological signs are largely overlapping. In a large proportion of cases, VMs are generated by somatic mosaicism in key genes, belonging to a few different molecular pathways. Therefore, molecular characterization may help in the understanding of the biological mechanisms related to the development of pathology. Tissue biopsy is not routinely included in the diagnostic path because of the need for fresh tissue specimens and the risk of bleeding. Bypassing the need for bioptic samples, we took advantage of the possibility of isolating cell-free DNA likely released by the affected tissues, to molecularly characterize 53 patients by cfDNA-NGS liquid biopsy. We found a good match between the identified variant and the clinical presentation. PIK3CA variants were found in 67% of Klippel Trenaunay Syndrome individuals; KRAS variants in 60% of arteriovenous malformations; MET was mutated in 75% of lymphovenous malformations. Our results demonstrate the power of cfDNA-NGS liquid biopsy in VMs clinical classification, diagnosis, and treatment. Indeed, tailored repurposing of pre-existing cancer drugs, such as PIK3CA, KRAS, and MET inhibitors, can be envisaged as adjuvant treatment, in addition to surgery and/or endovascular treatment, in the above-defined VMs categories, respectively.

1 March 2021 in Italian Journal of Vascular and Endovascular Surgery
Verified
Journal Article
Closed access
BLByung-Boong Lee
Byung-Boong Lee
MVMassimo Vaghi
Massimo Vaghi
Klippel-Trenaunay Syndrome (KTS) represents the archetype of vascular malformations and its eponym has been used for the individuation of practically all forms of vascular malformations. This is due to two reasons: the first is that the clinical picture of all different forms of vascular malformations represents the tip of an iceberg and the deep part may be discovered only using various diagnostic tools. The second is that it is a rare disease and also the physician treating this pathology are rare and have a difficulty to share the knowledge in the field of vascular malformations. KTS is a complex syndrome characterized by overgrowth of soft tissues, bone elongation or shortening, presence of skin naevus, anomalies in the superficial and deep veins, lymphatic vessels anomalies, visceral involvement. The patient may have all the described signs or the part but for the diagnosis of KTS the contemporary presence of at least two signs between tissue overgrowth, skin naevus and dilatation of superficial vein is mandatory. Regarding the hemodynamic aspects KTS is a slow-flow malformation on contrary to Parkes Weber Syndrome, which is a fast flow malformation, which remains the most crucial issue for the management. But such difficulty to differentiate clinically these two syndromes represents not only the lack of knowledge in this field in the first 80 years of the last century but also the lack of indifference. Hence proper understanding of its nature remains critical.

1 January 2009
Verified
Book Chapter
Closed access
PDF file
RMRaul Mattassi
Raul Mattassi
DLDirk A. Loose
Dirk A. Loose
MVMassimo Vaghi
Massimo Vaghi

1 January 2015
Verified
Book Chapter
Closed access
PDF file
RMRaul Mattassi
Raul Mattassi
DLDirk A. Loose
Dirk A. Loose
MVMassimo Vaghi
Massimo Vaghi

14 October 2010 in CardioVascular and Interventional Radiology
Verified
Journal Article
Closed access
PDF file
AIAnnamaria Ierardi
Annamaria Ierardi
MMMonica Mangini
Monica Mangini
MVMassimo Vaghi
Massimo Vaghi
ACAlberto Cazzulani
Alberto Cazzulani
RMRaul Mattassi
Raul Mattassi
GCGianpaolo Carrafiello
Gianpaolo Carrafiello